Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
AZELASTINE HYDROCHLORIDE ALLERGY vs CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine with mast cell stabilizing properties; selectively antagonizes histamine H1 receptors, reducing nasal pruritus, sneezing, rhinorrhea, and ocular symptoms.
Selective peripheral H1-receptor antagonist. Competitively inhibits histamine at the H1 receptor, preventing histamine-mediated symptoms such as pruritus, sneezing, and rhinorrhea.
One spray (137 mcg) per nostril twice daily (total 548 mcg/day). Intranasal route.
Oral, 10 mg once daily; may be increased to 10 mg twice daily if needed.
None Documented
None Documented
The terminal elimination half-life is approximately 22 hours (range 16-26 hours) at steady state, supporting twice-daily dosing. The half-life may be prolonged in elderly patients or those with hepatic impairment.
Terminal elimination half-life is approximately 8-11 hours in healthy adults; increases to approximately 20 hours in renal impairment (CrCl <40 mL/min).
Azelastine is primarily eliminated via renal excretion (approximately 75% as metabolites, <10% unchanged) and fecal excretion (approximately 25%) after oral administration. Biliary excretion is minimal.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; 10% is excreted in feces. Biliary excretion is minimal.
Category C
Category A/B
Antihistamine
Antihistamine